Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Baxter To Buy Prism, Getting Heart Drug

by Rick Mullin
April 25, 2011 | A version of this story appeared in Volume 89, Issue 17

Baxter International has agreed to acquire Prism Pharmaceuticals, a privately held drug firm that recently received FDA approval for the antiarrhythmic agent Nexterone. Baxter will pay $170 million at closing and up to $168 million in sales-based milestones. Sold as a ready-to-use premixed intravenous bag, Nexterone requires no admixing, Baxter says, thus eliminating the risk of medication errors as a result of compounding. Prism had previously selected Baxter as its contract manufacturer.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.